Lipoxins are a series of anti-inflammatory mediators. Lipoxins are short lived endogenously produced nonclassic eicosanoids whose appearance in inflammation signals the resolution of inflammation. They are abbreviated as LX, an acronym for lipoxygenase (LO) interaction products. At present two lipoxins have been identified; lipoxin A4 (LXA4) and lipoxin B4 (LXB4)
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent.
Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J.
Nat Med. 2006 Mar;12(3):330-4. Epub 2006 Jan 15.
PMID: 16415877
doi:10.1038/nm1355\n
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN.
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. Epub 2004 Oct 7.
PMID: 15471991
doi: 10.1073/pnas.0405445101
Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels.
Gangemi S, Pescara L, D'Urbano E, Basile G, Nicita-Mauro V, Davì G, Romano M.
Exp Gerontol. 2005 Jul;40(7):612-4.
PMID: 15935589
doi:10.1016/j.exger.2005.04.004
Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6.
Machado FS, Esper L, Dias A, Madan R, Gu Y, Hildeman D, Serhan CN, Karp CL, Aliberti J.
J Exp Med. 2008 May 12;205(5):1077-86. Epub 2008 Apr 14.
PMID: 18411340
doi:10.1084/jem.20072416
Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells.
Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C.
J Immunol. 2009 Mar 15;182(6):3819-26.
PMID: 19265161
doi:10.4049/jimmunol.0803175
Modulation of inflammation in brain: a matter of fat.
Farooqui AA, Horrocks LA, Farooqui T.
J Neurochem. 2007 May;101(3):577-99. Epub 2007 Jan 25. Review.
PMID: 17257165
DOI: 10.1111/j.1471-4159.2006.04371.x
RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis.
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE.
FASEB J. 2006 Feb;20(2):401-3. Epub 2005 Dec 22.
PMID: 16373400
doi:10.1096/fj.05-4724fje
Fatty acid facts, part III: Cardiovascular disease, or, a fish diet is noy fishy.
Pauwels EK, Kostkiewicz M.
Drug News Perspect. 2008 Dec;21(10):552-61.
PMID: 19221636
Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.\nDas UN.\nLipids Health Dis. 2008 Oct 15;7:37. Review.\nPMID: 18922179 \ndoi:10.1186/1476-511X-7-37